Key result
Multimodal salvage therapy provided durable disease control in highly selected patients with recurrent adrenocortical carcinoma, achieving a 5-year cancer-specific survival rate of 58%.
Why the study?
Adrenocortical carcinoma is an aggressive tumor that often recurs despite apparent complete resection, prompting an assessment of long-term outcomes following multimodal salvage therapy.
Does multimodal salvage therapy improve survival in patients with recurrent adrenocortical carcinoma?
Cohort (n=20)
Does multimodal salvage therapy improve survival in patients with recurrent adrenocortical carcinoma?
Multimodal salvage therapy, including surgery in selected patients, may provide long-term disease control and survival in recurrent adrenocortical carcinoma.
May support multimodal salvage in selected recurrent adrenocortical carcinoma; hypothesis-generating and requires prospective confirmation.
BACKGROUND: Adrenocortical carcinoma is an aggressive tumor which often recurs despite apparent complete resection. This study assessed the long-term outcomes for patients with recurrent adrenocortical carcinoma after multimodal salvage therapy with chemotherapy, chemoradiotherapy and surgery. METHODS: We retrospectively reviewed medical records of patients who had a pathological diagnosis of adrenocortical carcinoma between 1996 and 2017. Kaplan-Meier curves were used to assess progression-free and cancer-specific survivals among all patients and cancer-specific survival among patients with tumor recurrence. Log-rank test was used to compare patient survivals by modality of salvage therapy (chemotherapy, chemoradiotherapy and chemotherapy/chemoradiotherapy plus surgery). RESULTS: Of 20 patients who underwent initial surgery, recurrence occurred in 14 (70%) with a median interval of 7.5 (range 1.0-12.6) months. Salvage therapy provided was chemotherapy only (n = 7), chemoradiotherapy (n = 2) and chemotherapy/chemoradiotherapy plus surgery (n = 5). Of the five patients who received salvage surgery, three underwent repeated resections. The potential benefit of multimodal salvage therapy was suggested in five patients (4 with chemotherapy/chemoradiotherapy plus surgery and 1 with chemoradiotherapy) who achieved durable disease control (cancer-specific survival from initial recurrence, 22-258 months). With a median follow-up of 25 months from recurrence, the 5-year cancer-specific survival rate was 58%. cancer-specific survival after recurrence was prolonged in patients with ≤ stage 3 disease, positive response to chemotherapy/chemoradiotherapy and salvage surgery. CONCLUSIONS: Long-term disease control and survival could be achieved in highly selected patients with recurrent adrenocortical carcinoma using a multidisciplinary approach. Patients who had relatively limited recurrent sites and responded well to chemotherapy/chemoradiotherapy may be considered for salvage surgery on a case-by-case basis.
No takes yet. Share an insight, caveat, or question.
Kijima et al. (2023) conducted a cohort in recurrent adrenocortical carcinoma (n=20). Multimodal salvage therapy (chemotherapy, chemoradiotherapy, and surgery) vs. Different modalities compared (chemotherapy only vs chemoradiotherapy vs combination with surgery) was evaluated on 5-year cancer-specific survival rate. Multimodal salvage therapy provided durable disease control in highly selected patients with recurrent adrenocortical carcinoma, achieving a 5-year cancer-specific survival rate of 58%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: